Androgen Receptor Antagonist
High-dose androgens may ‘rewrite the textbooks’ on prostate cancer treatment
One journal reviewer told Donald P. McDonnell, PhD, the research should be “banned from the literature.”
VIDEO: Recent ARASENS trial results are ‘practice-changing’ in prostate cancer
Tanya Dorff, MD, section chief of the genitourinary disease program at City of Hope, spoke with Healio about results from the ARASENS trial presented at the 2022 ASCO Genitourinary Cancers Symposium.
Ipatasertib plus abiraterone improves radiographic PFS in prostate cancer with PTEN loss
The addition of ipatasertib to abiraterone enhanced antitumor activity and improved radiographic PFS as first-line therapy for metastatic castration-resistant prostate cancer, according to data presented at ESMO Virtual Congress 2020.
Darolutamide shows ‘high efficacy’ for nonmetastatic prostate cancer
Darolutamide conferred higher rates of 3-year OS than placebo among men with nonmetastatic castration-resistant prostate cancer, according to the final analysis of the ARAMIS trial published in The New England Journal of Medicine.
Angiotensin receptor antagonist use decreased after recalls for potentially carcinogenic impurities
The use of angiotensin II receptor antagonists, particularly generic valsartan, losartan and irbesartan, decreased since being recalled for potentially carcinogenic impurities, according to a research letter published in JAMA.